Goldman Scarlato & Karon, P.C. Announces Investigation of Clinical Data, Inc.
25 Febbraio 2011 - 4:56PM
Business Wire
Goldman Scarlato & Karon, P.C. (“GSK”) is investigating
potential legal claims against the Board of Directors of Clinical
Data, Inc. (“Clinical Data”) (NASDAQ: CLDA) relating to the
proposed buyout of Clinical Data by Forest Laboratories, Inc. The
definitive acquisition agreement, announced on February 22, 2011,
involves an all-cash, going-private transaction valued at
approximately $1.2 billion, or $30.00 per share. The acquisition
price reflects an 11.5 percent discount to Clinical Data’s February
18, 2011 closing price of $33.90.
The investigation relates to the fairness of the proposed
transaction to Clinical Data shareholders, possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Clinical Data for approving this transaction, and
whether Clinical Data’s Board of Directors acted
in shareholders’ best interests.
If you currently own shares of Clinical Data/CLDA and would like
additional information regarding this investigation, or if you have
information regarding the allegations involved in this transaction,
please contact Mark S. Goldman, Esq. at (888) 668-4130 or by
email at goldman@gsk-law.com.
About Goldman Scarlato & Karon, P.C.
GSK prosecutes securities fraud, consumer fraud, price-fixing,
ERISA class actions, and shareholder-derivative actions throughout
the United States. The Firm’s lawyers have recovered hundreds of
millions of dollars on behalf of consumers, investors, and
businesses.
To learn more about GSK, you may visit www.gsk-law.com.
Grafico Azioni Clinical Data (NASDAQ:CLDA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Clinical Data (NASDAQ:CLDA)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Clinical Data, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Goldman Scarlato & Karon, P.C. Articoli Notizie